Comparing two ways to guide cholesterol-lowering treatment after heart stent procedures
Compares apolipoprotein B-guided and LDL-cholesterol-guided cholesterol treatment in adults with coronary artery disease.
Plain-language title generated from the registry record
Registry title: Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention
Key facts
- Where
- Ho Chi Minh City, VietnamSee the site
Where in Vietnam
- University Medical Center Ho Chi Minh CityHo Chi Minh City, VietnamNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Medical Center Ho Chi Minh City (UMC)
- Trial code
- NCT06626126
- Record updated
- 16 October 2024
- Original description
This multicenter randomized trial is designed to assess the efficacy of lipid-lowering therapy in patients undergoing percutaneous coronary intervention, comparing an Apolipoprotein B-targeted approach with a Low-Density Lipoprotein Cholesterol (LDL-C)-targeted approach. The primary outcomes are to evaluate the proportion of patients achieving lipid-lowering treatment goals at the 1-year follow-up between the two treatment strategies: Apolipoprotein B-based therapy versus LDL-C-based therapy.Read full original descriptionShow less
Efficacy of Lipid-Lowering Therapy Based on Apolipoprotein B Versus LDL-Cholesterol Levels in Patients Undergoing Percutaneous Coronary Intervention: a Multicenter, Randomized Controlled Trial
This multicenter randomized trial is designed to assess the efficacy of lipid-lowering therapy in patients undergoing percutaneous coronary intervention, comparing an Apolipoprotein B-targeted approach with a Low-Density Lipoprotein Cholesterol (LDL-C)-targeted approach. The primary outcomes are to evaluate the proportion of patients achieving lipid-lowering treatment goals at the 1-year follow-up between the two treatment strategies: Apolipoprotein B-based therapy versus LDL-C-based therapy.
Inclusion: Patients aged 18 years or older; Patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES); Patients who agree to participate and provide informed consent.
Exclusion: Patients with contraindication to statin or other lipid-lowering therapy; Limited life expectancy: patients with a life expectancy of less than 12 months due to other non-cardiac conditions; Liver Disease: patients with cirrhosis or significant liver dysfunction; Any condition that may interfere with the study process, including treatment adherence or follow-up appointments (e.g., dementia, alcohol abuse, severe debilitation, long distances required for follow-up, etc.); Inability to Provide Informed Consent: Patients who are unable or unwilling to provide consent.